REGENXBIO Says FDA Placed Clinical Hold On RGX-121 For Hunter Syndrome After Asymptomatic Spine MRI Findings In Five CAMPSIITE Participants; Does Not Expect To Resubmit BLA In Near Term

Loading news article.

REGENXBIO Says FDA Placed Clinical Hold On RGX-121 For Hunter Syndrome After Asymptomatic Spine MRI Findings In Five CAMPSIITE Participants; Does Not Expect To Resubmit BLA In Near Term | WAPE

REGENXBIO Says FDA Placed Clinical Hold On RGX-121 For Hunter Syndrome After Asymptomatic Spine MRI Findings In Five CAMPSIITE Participants; Does Not Expect To Resubmit BLA In Near Term

Article summary

Related companies

Comments —